← boardnext 2027-01
LRMR
Larimar Therapeutics, Inc.distress 5/10 · elevated risk$3.99-1%today-33% from 52w high
Lead: Friedreich's ataxia
Revenue
pre-revenue
Liquidity
$178M
Runway
1.6 yrs
Shares 1y
+21%
Price & events
+15.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.7%
1D
+8.7%
1W
+8.4%
1M
-11.3%
3M
+8.1%
6M
+6.1%
1Y
-57.7%
2Y
-60.1%
5Y
-81.9%
All
Overview
- Market Cap
- $414.50M
- Volume
- 58.42K
- 52 Week Range
- $2.81 – $5.95
- Total Shares
- 103.88M
- Float Shares
- 59.94M
- Short %
- 18.13%
- % Held by Insiders
- 1.15%
- % Held by Institutions
- 86.06%
- RVOL
- 0.02x
- Beta
- 0.84
Pipeline stages · 2 programs
CTI-1601
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Nomlabofusp
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-01 Estimated 50% readout ~2027-02-15 | Phase 2 | CTI-1601 | Friedreich Ataxia | — | recruiting |
| 2025-04-28 | Phase 1 | Nomlabofusporphanrare pediatricfast trackbreakthrough | Friedreich Ataxia | 18 | terminated |
Catalyst news & presentations · 18
- second half of 2026Guided 55%regulatory submissionFiled (NDA/BLA)nomlabofusp · Submit CMC module to complete rolling BLASEC 8-K
- Q3 2026Guided 70%trial initiationsecondaryPhase 3nomlabofusp · First patient dosing in global confirmatory Phase 3 studySEC 8-K
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- Q2 2026readoutnomlabofusp · Topline open label study data to support BLA submissionSEC 8-K
- June 2026regulatory submissionFiled (NDA/BLA)nomlabofusp · Planned BLA submission seeking accelerated approvalSEC 8-K
- at time of BLA submission (Q2 2026)trial initiationsecondaryPhase 3nomlabofusp · Global Phase 3 confirmatory study expected to be underwaySEC 8-K
- 2026-06-29rolling reviewnomlabofusp · First module of rolling BLA submittedSEC 8-K
- 2H 2025regulatory submissionFiled (NDA/BLA)nomlabofusp · BLA filing to support accelerated approvalSEC 8-K
- later this yeartrial initiationsecondaryPhase 3nomlabofusp · Initiation of patient recruitment for global Phase 3 studySEC 8-K
- 2025-10-14fda agreementnomlabofusp · FDA agreed with modified dosing regimen after anaphylaxis casesSEC 8-K
- Sept 2025readoutnomlabofusp · Data in adolescent cohort of PK run-in studySEC 8-K
- 2025-06-30fda agreementnomlabofusp · FDA agreed to consider skin FXN as reasonably likely surrogate endpoint for accelerated approvalSEC 8-K
- mid-2025readoutnomlabofusp · 50 mg data from long-term OLE study.SEC 8-K
- mid-2025trial initiationsecondaryPhase 3nomlabofusp · Initiation of global confirmatory/registration study.SEC 8-K
- early 2025trial initiationsecondaryPhase 1nomlabofusp · Pediatric PK run-in study dosing expected early 2025SEC 8-K
- 2025-03-24fda agreementnomlabofusp · FDA stated openness to considering skin FXN concentration as a reasonably likely surrogate endpoint for accelerated approval, and acknowledged data support relationship between skin FXN and relevant tissues.SEC 8-K
- Q4 2024readoutnomlabofusp · Interim data from open-label extension studySEC 8-K
- by year-end 2024trial initiationsecondarynomlabofusp · PK run-in study in adolescents (12-17 years)SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $14 (+261% upside) · 10 analysts
- 2026-06-30BairdOutperform
- 2026-05-27JP MorganOverweight
- 2026-05-18WedbushOutperform
- 2026-03-20WedbushOutperform
- 2026-03-03WedbushOutperform
- 2026-02-25CitigroupBuy
Competitors — Friedreich's ataxia
Recent news
- 2026-07-23INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR - PR Newswire
- 2026-07-19Price to earnings forward of Larimar Therapeutics, Inc. – SWB:ZA71 - TradingView
- 2026-07-17INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR - YCharts
- 2026-07-15Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy - Yahoo Finance
- 2026-07-14Price to earnings forward of Larimar Therapeutics, Inc. – LS:A2P5PP - TradingView
- 2026-07-12Price to sales forward of Larimar Therapeutics, Inc. – NASDAQ:LRMR - TradingView
- 2026-07-10Thomas Hamilton Bought 6.1% More Shares In Larimar Therapeutics - Moomoo
- 2026-07-09INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR - PR Newswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.